ArticleBrazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas2026
COVID-19 mortality risk among women with ovarian cancer: a matched case-control study.
Article in Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Women with ovarian cancer may be at increased risk of severe COVID-19 outcomes. This study aimed to compare mortality and clinical outcomes between women with severe COVID-19, with and without a history of ovarian cancer. We conducted a matched case-control study using national surveillance data. Cases included women with severe COVID-19 and a history of ovarian cancer; controls were women with severe COVID-19 without such history. Matching was done at a 1:4 ratio using age, comorbidities, vaccination status, diagnosis date, and region. The primary outcome was COVID-19-related mortality. A total of 474 ovarian cancer cases and 1,896 controls were included. Mortality was significantly higher in women with ovarian cancer (54.9 vs 32.7%, P<0.001). Multivariate analysis showed that ovarian cancer increased the risk of death (OR: 2.76, 95%CI: 2.22-3.43). Age also influenced mortality: OR 2.57 (95%CI: 2.11-3.13) for women aged 65-84, and OR 3.86 (95%CI: 2.52-5.97) for those 85 and older. Vaccination provided protection: complete vaccination (OR: 0.67, 95%CI: 0.51-0.88) and complete vaccination plus booster (OR: 0.35, 95%CI: 0.27-0.47). Women with ovarian cancer had a significantly higher risk of death from severe COVID-19. Vaccination, particularly with a booster, was associated with 65% reduced mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.